8-K: BIOLASE Completes $7 Million Public Offering of Common Stock and Warrants

BIOLASE, Inc. successfully closed a $7 million public offering, issuing units consisting of common stock (or pre-funded warrants), Class A warrants, and Class B warrants.

Summary

• BIOLASE, Inc. has completed a public offering, raising approximately $7 million before fees and expenses.
• The offering included 7,795,000 units, each with one share of common stock, a Class A warrant, and a Class B warrant.
• Additionally, 8,205,000 pre-funded units were sold, each including a pre-funded warrant, a Class A warrant, and a Class B warrant.
• The common units were priced at $0.44 each, and the pre-funded units at $0.439 each.
• The Class A warrants are exercisable immediately at $0.66 per share and expire in five years.
• The Class B warrants are exercisable upon stockholder approval at $0.748 per share and expire five years after such approval.
• Pre-funded warrants are exercisable at $0.001 per share and can be exercised at any time until fully exercised.
• The company intends to use the net proceeds for working capital and general corporate purposes.
• A total of 7,205,000 shares of Common Stock were issued upon the exercise of Pre-Funded Warrants after the closing of the Offering, resulting in 1,000,000 Pre-Funded Warrants remaining outstanding.
• As of the close of business on February 15, 2024, the Company had a total of 19,195,024 shares of Common Stock outstanding.

Sentiment

Score: 5

Explanation: The document is neutral to slightly negative. While the company successfully raised capital, the terms of the offering, including the warrants and lock-up period, and the potential for delisting, temper the positive aspects. The company is also prohibited from entering into variable rate transactions for one year.

Positives

• The successful completion of the $7 million public offering provides the company with additional capital.
• The offering includes both common stock and warrants, potentially attracting a broader range of investors.
• The pre-funded warrants provide immediate capital to the company.

Negatives

• The offering includes warrants, which could dilute existing shareholders if exercised.
• The company is subject to a 90-day lock-up period on issuing further shares or equivalents.
• The company is prohibited from entering into variable rate transactions for one year.

Risks

• The company may be subject to delisting if it fails to evidence compliance with Nasdaq listing rules by March 31, 2024.
• The company is subject to a 90-day lock-up period on issuing further shares or equivalents.
• The company is prohibited from entering into variable rate transactions for one year.
• There is no established trading market for the Pre-Funded Warrants or the Common Warrants and the Company does not expect a market to develop.

Future Outlook

The company intends to use the net proceeds from the offering for working capital and general corporate purposes.

Industry Context

This offering is a common method for companies to raise capital, particularly those in the medical device sector that require funding for research, development, and commercialization. The inclusion of warrants is a typical incentive for investors in such offerings.

Comparison to Industry Standards

• The structure of this offering, with units consisting of common stock and warrants, is a common practice in the biotech and medical device industries, similar to offerings by companies like Xtant Medical Holdings, Inc. and PAVmed Inc.
• The pricing of the units at $0.44 and $0.439 is typical for companies with a lower share price, and the exercise prices of the warrants are generally set at a premium to the offering price, similar to other offerings in the sector.
• The use of proceeds for working capital and general corporate purposes is standard for companies in this stage of development, comparable to other companies in the medical device space.

Stakeholder Impact

• Shareholders may experience dilution if warrants are exercised.
• The company's ability to raise additional capital in the near term is limited by the lock-up period.
• The company's ability to execute its business plan is enhanced by the additional capital.

Next Steps

• The company will seek stockholder approval for the Class B warrants.
• The company will use the net proceeds for working capital and general corporate purposes.
• The company will need to evidence compliance with Nasdaq listing rules by March 31, 2024.

Key Dates

Keywords

public offering, common stock, warrants, pre-funded warrants, capital raise, BIOLASE, securities, stockholder approval, Nasdaq